{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T17:47:57Z","timestamp":1762278477196,"version":"build-2065373602"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T00:00:00Z","timestamp":1746835200000},"content-version":"vor","delay-in-days":9,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018688","name":"Korea Disease Control and Prevention Agency","doi-asserted-by":"publisher","award":["6331-301-210-13"],"award-info":[{"award-number":["6331-301-210-13"]}],"id":[{"id":"10.13039\/100018688","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.vaccine.2025.127212","type":"journal-article","created":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T11:39:13Z","timestamp":1746790753000},"page":"127212","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Serological correlates of protection and long-term efficacy of a novel recombinant protective antigen-based anthrax vaccine in a rabbit model"],"prefix":"10.1016","volume":"57","author":[{"given":"Gyu-Lee","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seong Wook","family":"Pyo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"So-Hyeon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyun-Ju","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang-Yoon","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hwajung","family":"Yi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gi-eun","family":"Rhie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoon-Seok","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2025.127212_bb0005","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.3390\/ani12091146","article-title":"Seasonality and ecological suitability modelling for Anthrax (bacillus anthracis) in Western Africa","volume":"12","author":"Pittiglio","year":"2022","journal-title":"Animals (Basel)"},{"key":"10.1016\/j.vaccine.2025.127212_bb0010","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.3390\/toxins7083167","article-title":"Anthrax toxins in context of bacillus anthracis spores and spore germination","volume":"7","author":"Cote","year":"2015","journal-title":"Toxins"},{"key":"10.1016\/j.vaccine.2025.127212_bb0015","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/dmp.2011.71","article-title":"Anthrax attacks: lessons learned on the 10th anniversary of the anthrax attacks","volume":"5","author":"Zink","year":"2011","journal-title":"Disaster Med Public Health Prep"},{"key":"10.1016\/j.vaccine.2025.127212_bb0020","first-page":"175","article-title":"Bacillus anthracis as a biological warfare agent: infection, diagnosis and countermeasures","volume":"121","author":"Pohanka","year":"2020","journal-title":"Bratisl Lek Listy"},{"key":"10.1016\/j.vaccine.2025.127212_bb0025","first-page":"13","article-title":"Anthrax in humans, animals, and the environment and the one health strategies for Anthrax control","author":"Subedi","year":"2024","journal-title":"Pathogens"},{"key":"10.1016\/j.vaccine.2025.127212_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.resmic.2023.104029","article-title":"The persistence of time: the lifespan of bacillus anthracis spores in environmental reservoirs","volume":"174","author":"Barandongo","year":"2023","journal-title":"Res Microbiol"},{"key":"10.1016\/j.vaccine.2025.127212_bb0035","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1038\/s41564-019-0435-4","article-title":"The global distribution of bacillus anthracis and associated anthrax risk to humans, livestock and wildlife","volume":"4","author":"Carlson","year":"2019","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.vaccine.2025.127212_bb0040","doi-asserted-by":"crossref","first-page":"690","DOI":"10.3390\/pathogens11060690","article-title":"What is anthrax?","volume":"11","author":"Bower","year":"2022","journal-title":"Pathogens"},{"key":"10.1016\/j.vaccine.2025.127212_bb0045","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jiph.2010.07.004","article-title":"A review of cutaneous anthrax and its outcome","volume":"3","author":"Doganay","year":"2010","journal-title":"J Infect Public Health"},{"key":"10.1016\/j.vaccine.2025.127212_bb0050","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.3201\/eid2704.204496","article-title":"High case-fatality rate for human anthrax, northern Ghana, 2005-2016","volume":"27","author":"Blackburn","year":"2021","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127212_bb0055","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1186\/s12889-021-10275-0","article-title":"Investigation of an anthrax outbreak in Makoni District","volume":"21","author":"Makurumidze","year":"2021","journal-title":"Zimbabwe BMC Public Health"},{"key":"10.1016\/j.vaccine.2025.127212_bb0060","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0009645","article-title":"Cutaneous anthrax associated with handling carcasses of animals that died suddenly of unknown cause: Arua District, Uganda, January 2015-august 2017","volume":"15","author":"Aceng","year":"2021","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2025.127212_bb0065","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s10393-021-01549-5","article-title":"Climatic factors influencing the Anthrax outbreak of 2016 in Siberia","volume":"18","author":"Ezhova","year":"2021","journal-title":"Russia EcoHealth"},{"key":"10.1016\/j.vaccine.2025.127212_bb0070","doi-asserted-by":"crossref","first-page":"833","DOI":"10.4269\/ajtmh.18-0224","article-title":"Recurrent Anthrax outbreaks in humans, livestock, and wildlife in the same locality, Kenya, 2014-2017","volume":"99","author":"Muturi","year":"2018","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2025.127212_bb0075","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1128\/CVI.00324-12","article-title":"A three-dose intramuscular injection schedule of anthrax vaccine adsorbed generates sustained humoral and cellular immune responses to protective antigen and provides long-term protection against inhalation anthrax in rhesus macaques","volume":"19","author":"Quinn","year":"2012","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2025.127212_bb0080","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1080\/21645515.2020.1799668","article-title":"Characterization of the UK anthrax vaccine and human immunogenicity","volume":"17","author":"Modi","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2025.127212_bb0085","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1128\/CVI.00099-13","article-title":"Evaluation of immunogenicity and efficacy of anthrax vaccine adsorbed for postexposure prophylaxis","volume":"20","author":"Ionin","year":"2013","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2025.127212_bb0090","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1128\/CVI.00469-14","article-title":"Comprehensive analysis and selection of anthrax vaccine adsorbed immune correlates of protection in rhesus macaques","volume":"21","author":"Chen","year":"2014","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2025.127212_bb0095","doi-asserted-by":"crossref","first-page":"6163","DOI":"10.1016\/j.vaccine.2022.08.052","article-title":"Serological responses to Anthrax vaccine precipitated (AVP) increase with time interval between booster doses","volume":"40","author":"Dyson","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127212_bb0100","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41541-019-0102-z","article-title":"Single dose of DPX-rPA, an enhanced-delivery anthrax vaccine formulation, protects against a lethal bacillus anthracis spore inhalation challenge","volume":"4","author":"Weir","year":"2019","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.vaccine.2025.127212_bb0105","first-page":"4","article-title":"Anthrax outbreak: exploring its biological agents and public health implications","author":"Ogunleye","year":"2024","journal-title":"Front Trop Dis"},{"key":"10.1016\/j.vaccine.2025.127212_bb0110","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2217\/17460913.4.1.35","article-title":"Anti-toxin antibodies in prophylaxis and treatment of inhalation anthrax","volume":"4","author":"Schneemann","year":"2009","journal-title":"Future Microbiol"},{"key":"10.1016\/j.vaccine.2025.127212_bb0115","doi-asserted-by":"crossref","first-page":"5978","DOI":"10.1128\/IAI.73.9.5978-5987.2005","article-title":"Immunogenicity of recombinant protective antigen and efficacy against aerosol challenge with anthrax","volume":"73","author":"Williamson","year":"2005","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2025.127212_bb0120","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/S0264-410X(97)00268-5","article-title":"Protective efficacy of a recombinant protective antigen against bacillus anthracis challenge and assessment of immunological markers","volume":"16","author":"McBride","year":"1998","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127212_bb0125","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1016\/j.vaccine.2022.01.047","article-title":"Safety and immunogenicity of a plant-derived recombinant protective antigen (rPA)-based vaccine against bacillus anthracis: a phase 1 dose-escalation study in healthy adults","volume":"40","author":"Paolino","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127212_bb0130","doi-asserted-by":"crossref","first-page":"7970","DOI":"10.1016\/j.vaccine.2020.10.053","article-title":"Evaluation of BioThrax and AV7909 anthrax vaccines in adults 66 years of age or older","volume":"38","author":"Wolfe","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127212_bb0135","doi-asserted-by":"crossref","first-page":"3820","DOI":"10.1016\/j.vaccine.2019.05.057","article-title":"Immunogenicity and safety of a novel recombinant protective antigen anthrax vaccine (GC1109), a randomized, single-blind, placebo controlled phase II clinical study","volume":"37","author":"Kang","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127212_bb0140","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/j.vaccine.2019.12.048","article-title":"Evaluation of the protective efficacy of recombinant protective antigen vaccine (GC1109)-immunized human sera using passive immunization in a mouse model","volume":"38","author":"Jo","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127212_bb0145","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.dci.2018.10.003","article-title":"Rabbit models of human diseases for diagnostics and therapeutics development","volume":"92","author":"Mage","year":"2019","journal-title":"Dev Comp Immunol"},{"key":"10.1016\/j.vaccine.2025.127212_bb0150","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.1016\/j.vaccine.2023.04.002","article-title":"Immunogenicity and protective efficacy of recombinant protective antigen anthrax vaccine (GC1109) in A\/J mice model","volume":"41","author":"Kim","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127212_bb0155","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/0264-410X(95)00139-R","article-title":"Experimental anthrax vaccines: efficacy of adjuvants combined with protective antigen against an aerosol bacillus anthracis spore challenge in guinea pigs","volume":"13","author":"Ivins","year":"1995","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127212_bb0160","doi-asserted-by":"crossref","first-page":"151ra126","DOI":"10.1126\/scitranslmed.3004073","article-title":"Anthrax vaccine-induced antibodies provide cross-species prediction of survival to aerosol challenge","volume":"4","author":"Fay","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2025.127212_bb0165","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3389\/fimmu.2018.00026","article-title":"Assessing the importance of domestic vaccine manufacturing centers: an overview of immunization programs, vaccine manufacture, and distribution","volume":"9","author":"Rey-Jurado","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2025.127212_bb0170","doi-asserted-by":"crossref","first-page":"e835","DOI":"10.1542\/peds.2008-1092","article-title":"Temporary vaccine recommendations and provider compliance: a survey of pediatric practices during the 2003-2004 pneumococcal conjugate vaccine shortage","volume":"122","author":"Groom","year":"2008","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2025.127212_bb0175","series-title":"Presentation to the Institute of Medicine Committee to assess the safety and efficacy of the Anthrax vaccine, Meeting III, Washington, D.C","article-title":"Animal models for anthrax vaccine efficacy","author":"Pitt","year":"2001"},{"key":"10.1016\/j.vaccine.2025.127212_bb0180","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.1016\/j.vaccine.2017.07.076","article-title":"Correlation between anthrax lethal toxin neutralizing antibody levels and survival in guinea pigs and nonhuman primates vaccinated with the AV7909 anthrax vaccine candidate","volume":"35","author":"Savransky","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127212_bb0185","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1128\/IAI.69.5.2888-2893.2001","article-title":"Search for correlates of protective immunity conferred by anthrax vaccine","volume":"69","author":"Reuveny","year":"2001","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2025.127212_bb0190","doi-asserted-by":"crossref","first-page":"16013","DOI":"10.1038\/npjvaccines.2016.13","article-title":"First vaccine approval under the FDA animal rule","volume":"1","author":"Beasley","year":"2016","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.vaccine.2025.127212_bb0195","doi-asserted-by":"crossref","first-page":"6333","DOI":"10.1016\/j.vaccine.2021.08.075","article-title":"Safety and immunogenicity of Px563L, a recombinant anthrax vaccine candidate, in a two-dose regimen for post-exposure prophylaxis in healthy adults","volume":"39","author":"Schneider","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127212_bb0200","doi-asserted-by":"crossref","first-page":"eadg2122","DOI":"10.1126\/sciadv.adg2122","article-title":"Repetitive mRNA vaccination is required to improve the quality of broad-spectrum anti-SARS-CoV-2 antibodies in the absence of CXCL13","volume":"9","author":"Azarias Da Silva","year":"2023","journal-title":"Sci Adv"},{"key":"10.1016\/j.vaccine.2025.127212_bb0205","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1016\/j.vaccine.2017.05.008","article-title":"Waning protection following 5 doses of a 3-component diphtheria, tetanus, and acellular pertussis vaccine","volume":"35","author":"Klein","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127212_bb0210","first-page":"647","article-title":"Centers for Disease Control and Prevention. Yellow fever vaccine booster doses: recommendations of the advisory committee on immunization practices, 2015","volume":"64","author":"Staples","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2025.127212_bb0215","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1080\/14760584.2022.2071705","article-title":"Repeated vaccination and \u2018vaccine exhaustion\u2019: relevance to the COVID-19 crisis","volume":"21","author":"Azim Majumder","year":"2022","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2025.127212_bb0220","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1016\/j.vaccine.2020.03.025","article-title":"Negative effect on immune response of repeated influenza vaccination and waning effectiveness in interseason for elderly people","volume":"38","author":"Sugishita","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127212_bb0225","doi-asserted-by":"crossref","first-page":"2290345","DOI":"10.1080\/21645515.2023.2290345","article-title":"Efficacy of different AV7909 dose regimens in a nonclinical model of pulmonary anthrax","volume":"19","author":"Henning","year":"2023","journal-title":"Hum Vaccin Immunother"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25005092?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25005092?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T17:43:16Z","timestamp":1762278196000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X25005092"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":45,"alternative-id":["S0264410X25005092"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127212","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serological correlates of protection and long-term efficacy of a novel recombinant protective antigen-based anthrax vaccine in a rabbit model","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127212","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"127212"}}